Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=4&sort=awardee_organization
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=awardee_organization", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1397&sort=awardee_organization", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=5&sort=awardee_organization", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=awardee_organization" }, "data": [ { "type": "Grant", "id": "8222", "attributes": { "award_id": "75N92021C00008-0-9999-1", "title": "AWARD A CONTRACT FOR RADX TECH - QORVO TO SECURE AN EUA APPROVED POC ANTIGEN TEST SYSTEM AS WELL AS INCREASE AN INCREMENTAL DAILY CARTRIDGE PRODUCTION", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-04-02", "end_date": "2022-04-01", "award_amount": 24361759, "principal_investigator": { "id": 24054, "first_name": "HANJOON", "last_name": "RYU", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Qorvo Biotechnologies’ (Qorvo) investigational Bulk Acoustic Wave (BAW) sensor detection platform (Omnia TM ) targets viral antigen testing for use in Point-of-Care (POC) settings. The platform is designed to produce reliable and quantitative results matching central lab performance and improving confidence in POC tests. Developed over a 6+ year timeframe, the technological differentiation is in the detection core, where Qorvo has optimized the BAW device that is made at low cost and high volume (millions per day for cell phones) for liquid biosensing. Detection of SARS-CoV-2 antigen occurs with a shift in the biosensor resonance frequency as antigen (Nucleocapsid and Spike S1) protein mass accumulates at specific probes on the sensor surface. Traditional optical/ fluorescence sensing is replaced by high-sensitivity, high-specificity solid-state mass-based sensing. While this proposal is focused on antigen test development, Qorvo has submitted for a SARS-CoV-2 IgG antibody test EUA on the same BAW platform that was completed in less than 10 weeks with world-class performance of 100% specificity and 100% negative cross reactivity. Given this is just one of over a dozen other assays previously run through this platform, the results give us extreme confidence in our ability to execute the viral antigen technical and timeline tasks. Qorvo has invested heavily in manufacturing infrastructure commercial development for the antibody test as well as existing veterinary and human development products so the antigen will be part of a product suite. RADx assistance will enable acceleration of regulatory and US-based high-volume manufacturing ramp.", "keywords": [ "2019-nCoV", "Acceleration", "Acoustics", "Antigens", "Biological Assay", "Biosensing Techniques", "Biosensor", "Cellular Phone", "Contracts", "Detection", "Development", "Devices", "Fluorescence", "Frequencies", "Human Development", "Immunoglobulin G", "Infrastructure", "Investigation", "Liquid substance", "Nucleocapsid", "Optics", "Performance", "Production", "Proteins", "RADx", "RADx Tech", "Ramp", "Running", "SARS-CoV-2 antigen", "Secure", "Specificity", "Surface", "System", "TimeLine", "Viral Antigens", "antibody test", "antigen test", "base", "cost", "cross reactivity", "design", "detection platform", "improved", "point of care", "point of care testing", "product development", "sensor", "solid state" ], "approved": true } }, { "type": "Grant", "id": "9299", "attributes": { "award_id": "75N92020C00033-P00001-9999-1", "title": "RADX TECH PROJECT #4554: UBIQUITOME SARS-COV-2 LAB TEST ACCURACY WITHIN REACH OF EVERY AMERICAN WITH LIBERTY16 MOBILE REAL TIME PCR", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-29", "end_date": "2021-09-28", "award_amount": 1760000, "principal_investigator": { "id": 25039, "first_name": "PAUL", "last_name": "PICKERING", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Gold standard SARS-CoV-2 testing (100% specificity, 100% sensitivity) has been available in America February 4, 2020, through the FDA CDA real time PCR test, yet it is still not available to many Americans who need it. Recent attempts to make SARS-CoV-2 testing more accessible (e.g. Abbott & Quidel) has been plagued by low throughput (single sample at a time) and high false negatives. What is needed is the CDC’s FDA authorized gold standard real time PCR testing within reach of every American. We propose to engage in a rapid enhancement and scaling program for our commercial mobile Liberty16 system that will allow this fully mobile real time PCR device to exceed the throughput- based gold standard 96-well based workflows in centralized labs while offering the same low false negative levels (<5%) observed with the CDC test. Enhanced Functionality. We will fast-track implemetation of several planned features that substantially enhance the throughput and user interface of the exisiting Liberty16 system: (1) Implementation of multiplex capability enabling single-well detection of multiple targets. This increases sample capacity from 3 to 14 (plus controls) per run. (2) Implementation of software and minor hardware modifications that significantly reduce the run time from 40 minutes to 25 minutes or less. (3) Update the Liberty16 iPhone/iPad user interface to include (i) a barcode reader for sample identifier input; (ii) automated reporting of multiplexed assays. (4) Optimize a safe sample collection and preparation workflow for saliva, enabling setup completion in under 5 minutes and with minimal processing steps.", "keywords": [ "2019-nCoV", "American", "Americas", "Bar Codes", "COVID-19 testing", "Cellular Phone", "Centers for Disease Control and Prevention (U.S.)", "Computer software", "Detection", "Devices", "Gold", "Minor", "Modification", "Preparation", "RADx Tech", "Reader", "Reporting", "Running", "Saliva", "Sampling", "Specificity", "System", "Testing", "Time", "Update", "base", "multiplex assay", "programs", "sample collection" ], "approved": true } }, { "type": "Grant", "id": "13498", "attributes": { "award_id": "75N95020D00011-0-759502300002-1", "title": "NCATS CYBERSECURITY SERVICES DIVISION PROGRAM SUPPORT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-09-29", "end_date": "2024-02-28", "award_amount": 1427260, "principal_investigator": { "id": 29624, "first_name": "", "last_name": "", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, https://covid.cd2h.org/, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, the National Center for Data to Health (CD2H), and the NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), with overall stewardship by NCATS. The N3C program is essentially a medium sized business, consisting of thousands of researchers, requiring enterprise level information technology (IT) support as part of a virtual research organization (VRO). This contract is necessary to ensure that NCATS and N3C can continue to provide adequate support for a secure, collaborative, VRO. This contract allows for continued support of the VRO which supports all of the required information technology functions to support an environment of over 4,000 users, including cloud-based productivity tools, a service desk, commercial and open-source deployments of analytical tools for the community to use, and expansion of the data types available for analysis, such as imaging, viral variant genomic sequences, etc. The common need is to share a collaborative cloud environment capable of ingesting billions of data points and performing a variety of complex analyses against multimodal data types, ranging from pathology and radiology data, synthetic data, genomic information, electronic health records (EHRs) and a wide variety of others. All of this must be done while meeting the highest levels of security and privacy, given the sensitivity of some of the data types being collected and the importance of the work being done in the environment. This contract provides IT security support for all of these enterprise IT efforts.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8070", "attributes": { "award_id": "75N92021P00061-0-0-1", "title": "EXERCISE OPTION PERIOD 2 TO PROVIDE SERVICES IN SUPPORT OF NIBIB COVID-19 RADX PROJECT FOR THE PERIOD 10/16/2021 - 01/31/2022", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)", "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-02-01", "end_date": "2021-05-31", "award_amount": 14871886, "principal_investigator": { "id": 23963, "first_name": "ELIAS", "last_name": "CARO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has an open solicitation for proposals to provide up to $500 million across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.", "keywords": [ "American", "COVID-19", "COVID-19 detection", "COVID-19 diagnostic", "COVID-19 testing", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Contracts", "Department of Defense", "Development", "Device Designs", "Diagnostic tests", "Ensure", "Exercise", "Exhalation", "Funding", "Goals", "Home", "Improve Access", "Laboratories", "Life Cycle Stages", "Modification", "National Institute of Biomedical Imaging and Bioengineering", "Patients", "Performance", "Point of Care Technology", "Privatization", "Program Development", "RADx", "Readiness", "Research", "Saliva", "Sampling", "Seasons", "Sensitivity and Specificity", "Services", "Speed", "Structure", "Technology", "Test Result", "Testing", "Time", "TimeLine", "United States National Institutes of Health", "Validation", "Virus", "base", "commercialization", "cost", "design", "detection limit", "flu", "handheld mobile device", "home test", "improved", "innovation", "meetings", "novel", "point of care", "product development", "programs", "scale up", "technology development", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "4728", "attributes": { "award_id": "NNX13AG97G", "title": "DROUGHT ACCOUNTS FOR WIDE SPREAD AGRICULTURAL FAILURE, SIGNIFICANT LOSS OF LIFE THROUGH FAMINE, AND DECLINES IN NATIONAL GDP FOR MANY COUNTRIES, WITH NEARLY 1.9 BILLION PEOPLE HAVING BEEN AFFECTED BY DROUGHT IN THE 20TH C. ACCURATE AND HIGH-RESOLUTION REA", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2013-02-11", "end_date": "2017-02-10", "award_amount": 0, "principal_investigator": { "id": 16385, "first_name": "ERIC", "last_name": "WOOD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "DROUGHT ACCOUNTS FOR WIDE SPREAD AGRICULTURAL FAILURE, SIGNIFICANT LOSS OF LIFE THROUGH FAMINE, AND DECLINES IN NATIONAL GDP FOR MANY COUNTRIES, WITH NEARLY 1.9 BILLION PEOPLE HAVING BEEN AFFECTED BY DROUGHT IN THE 20TH C. ACCURATE AND HIGH-RESOLUTION REA", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9280", "attributes": { "award_id": "75N91020C00035-0-9999-1", "title": "DIGITAL HEALTH SOLUTIONS FOR COVID-19: CLEAR2GO", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-14", "end_date": "2020-11-27", "award_amount": 274880, "principal_investigator": { "id": 25020, "first_name": "ADARBAD", "last_name": "MASTER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1816, "ror": "", "name": "ICRYPTO, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": null, "abstract": "The goal of this project is to develop a smartphone-based platform to provide irrefutable proof of testing, serologic, and vaccination status for individuals. The customized solution, called Clear2Go (C2G), maps a person’s vetted identity and biometrics to their phone and then cryptographically binds it with their COVID-19 test results or other personal health information. C2G is intended to provide individuals, employers, government agencies, and other organizations with a convenient solution to evaluate the risks associated with an individual’s return to normal work, travel, and public life activities. The aims of this project include creating the C2G solution, demonstrating that C2G can be integrated with the publicly available interface of a test laboratory portal, and conveying simulated COVID-19 test results into the C2G application. Data collected under this project will be deidentified and securely transmitted to an NIH data hub.", "keywords": [ "Binding", "Biometry", "COVID-19", "Cellular Phone", "Custom", "Data", "Goals", "Government Agencies", "Health", "Individual", "Laboratories", "Life", "Maps", "Persons", "Risk", "Secure", "Serological", "Telephone", "Test Result", "Testing", "Travel", "United States National Institutes of Health", "Vaccination", "Work", "base", "cryptography", "data hub", "digital" ], "approved": true } }, { "type": "Grant", "id": "10379", "attributes": { "award_id": "75N93022C00044-0-9999-1", "title": "SBIR TOPIC 107 REAGENTS FOR IMMUNOLOGIC ANALYSIS OF NON- MAMMALIAN AND UNDERREPRESENTED MAMMALIAN MODELS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2024-09-29", "award_amount": 596519, "principal_investigator": { "id": 24917, "first_name": "TORI", "last_name": "RACE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The hamster is a well-established model for several infectious diseases including influenza and SARS-CoV-2. Lack of hamster reagents has hampered pre-clinical studies of viral pathogenesis, host immunity, and vaccine development. The objectives of this proposal are to produce and test monoclonal antibodies against 10 cytokines and chemokines and 4 T cell surface markers for characterizing cytokine responses and examining T cells activation in the hamster models of respiratory infections. Completion of this project will provide high-affinity monoclonal antibodies that allow investigators to distinguish innate and adaptive inflammatory cytokine and chemokine responses as well as activated T cells, memory T cells, tissue resident memory T cells, and regulatory T cells in the hamster models of infectious diseases.", "keywords": [ "2019-nCoV", "Affinity", "Cell surface", "Cells", "Communicable Diseases", "Generations", "Hamsters", "Immunity", "Immunization", "Immunologics", "Inflammatory", "Influenza", "Memory", "Modeling", "Monoclonal Antibodies", "Mus", "Proteins", "Reagent", "Recombinant Proteins", "Recombinants", "Regulatory T-Lymphocyte", "Research Personnel", "Respiratory Tract Infections", "Serum", "Small Business Innovation Research Grant", "T memory cell", "T-Cell Activation", "T-Lymphocyte", "Testing", "Tissue Sample", "Tissues", "Validation", "Viral Pathogenesis", "chemokine", "cytokine", "infectious disease model", "preclinical study", "response", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "7780", "attributes": { "award_id": "1ZIAMD000006-06", "title": "Understanding and reducing health disparities through social and behavioral research", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [], "start_date": null, "end_date": null, "award_amount": 443383, "principal_investigator": { "id": 23586, "first_name": "Kelvin", "last_name": "Choi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Understanding inter-relationships between social determinants and tobacco use With the increase in e-cigarette use in the US, we examined whether e-cigarette use can reduce disparities in cigarette smoking in the US. We analyzed the Tobacco Use Supplement of the Current Population Survey (TUS-CPS) and found that the prevalence of daily e-cigarette use, a behavior that is associated with smoking cessation, is low in the US adult smoker population. Additionally, the prevalence is particularly low among non-Hispanic Blacks, suggesting the e-cigarettes may increase smoking disparities by race. In a different study, we analyzed the Population Assessment of Tobacco and Health (PATH) study data to examine the association between secondhand smoke exposure and subsequent academic performance among youth. We found that youth who were exposed to more secondhand smoke (measured by hours per week) had lower subsequent academic performance compared to those who were not exposed to secondhand smoke. This finding suggests that secondhand smoke exposure could influence academic performance, which I an important factor for enrolling in post-secondary education. Investigate mediating and moderating factors associated with tobacco use disparities We continue to examine how tobacco marketing influence tobacco use behaviors. We analyzed data from the Population Assessment of Tobacco and Health (PATH) study and found that exposure to e-cigarette marketing is associated with subsequent e-cigarette experimentation among youth and young adult. In a focus group study with a racial/ethnically diverse group of young adult smokers, we explored their perceptions related to smoking cessation treatments, and found that many of them expressed negative perceptions toward these treatments. These findings indicate the need to better communicate efficacy of these treatment and facilitate access to them among young adult smokers, especially those in racial/ethnic minority populations. In collaboration with the PATH Study team, we examined how harm perceptions of tobacco products changes over time and how they relate to tobacco use behaviors. We found that perceived tobacco products to be harm was associated with not using the product, but use of product was also associated with lower harm perception subsequently. This highlight the importance of matching health risk messages with tobacco use behaviors to prevent tobacco use vs. promote cessation. In a separate analysis, we worked with the PATH Study team to examine if e-cigarette and pharmacotherapy use among smokers attempting to quit smoking are associated with long-term smoking cessation. We found that e-cigarette use, nor pharmacotherapy, was associated with long-term smoking cessation. This provides evidence on whether e-cigarettes should be used for smoking cessation, and highlight the limited efficacy of the current pharmacotherapy for smoking cessation. Investigate the impact of tobacco use patterns and health outcomes Through a collaboration with extramural investigators, we examined the Youth Risk Behavioral Survey data and found that e-cigarette use was associated with asthma among youth, independent of cigarette and marijuana use. This provides additional evidence on the possible health impact of e-cigarette on youth respiratory health. COVID-19 and Tobacco Use We have developed a study to examine how COVID-19 impact adult tobacco users, and how they have modified their tobacco use behaviors accordingly. The study has complete internal review and is schedule to launch in late FY2020.", "keywords": [ "Address", "Adult", "Advertising", "Area", "Asthma", "Behavior", "Behavioral", "Behavioral Research", "COVID-19", "Cessation of life", "Characteristics", "Collaborations", "Complex", "Data", "Data Analyses", "Databases", "Economics", "Education", "Electronic cigarette", "Enrollment", "Epidemiology", "Exposure to", "Extramural Activities", "Focus Groups", "Goals", "Health", "Health Communication", "Health Personnel", "Hour", "Individual", "Intervention", "Marketing", "Measures", "Mediating", "Modeling", "Not Hispanic or Latino", "Outcome", "Pattern", "Perception", "Performance", "Pharmacotherapy", "Population", "Population Analysis", "Population Assessment of Tobacco and Health", "Prevalence", "Price", "Public Health", "Reporting", "Research", "Research Personnel", "Risk", "Schedule", "Secondary Schools", "Smoker", "Smoking", "Smoking Cessation Intervention", "Social Marketing", "Surgeon", "Surveys", "Time", "Tobacco Industry", "Tobacco use", "Treatment Efficacy", "Vision", "Work", "Youth", "behavioral health", "cigarette smoking", "demographics", "disadvantaged population", "disparity reduction", "electronic cigarette use", "environmental tobacco smoke", "environmental tobacco smoke exposure", "ethnic diversity", "ethnic minority population", "health disparity", "insight", "marijuana use", "mortality", "novel", "population based", "population health", "population survey", "racial and ethnic", "racial disparity", "reduce tobacco use", "respiratory health", "sleep quality", "smoking cessation", "smoking prevalence", "social", "social determinants", "social health determinants", "socioeconomics", "tobacco advertising", "tobacco control", "tobacco prevention", "tobacco products", "tobacco user", "young adult" ], "approved": true } }, { "type": "Grant", "id": "9115", "attributes": { "award_id": "75N92020C00010-P00001-9999-1", "title": "RADX TECH - TALIS BIOMEDICAL HIGHLY SCALABLE SARS-COV-2 RNA DETECTION IN MINUTES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-30", "end_date": "2021-07-29", "award_amount": 9750000, "principal_investigator": { "id": 24901, "first_name": "JENNIFER", "last_name": "BALDWIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "With over $100M investment by the top biotech Venture Capital funds, NIH, CARB-X, and DARPA, Talis has developed ultrafast, sensitive, scalable technology uniquely suitable for COVID-19 testing. The Talis technology performs rapid (as fast as 6 minutes) purification of SARS-CoV-2 RNA from large volumes of human specimens including swabs and saliva and detects SARS-CoV-2 RNA in under 5 minutes for high positives and under 10 minutes near the limit of detection (~10 copies/reaction). Talis will deploy this technology in a high-throughput format for laboratories (Talis HT) and at the point-of-care (POC) for minimally trained users (Talis One). With RADx support, Talis will scale this technology in three stages: (1) In June, to accelerate throughput of the currently installed diagnostic equipment, Talis will deliver reagent kits for rapid SARS-CoV-2 detection in 96-well format. (2) In July, to further increase testing throughput, Talis will launch automation solutions for common diagnostic laboratory platforms, making kits for 4 million tests available. (3) In September, Talis will launch its rapid COVID-19 Talis One POC test on a multiplexed cartridge, expandable to include influenza. Operated by a compact Talis One instrument, this cartridge enables fully automated, sensitive SARS-CoV-2 RNA detection in under 20 minutes. Talis HT and Talis One will be adaptable to mobile testing for rapid response contact tracing, worker screening, and outbreak response. Talis is requesting RADx support to scale up and accelerate manufacturing of tests and will commit significant funds for cost-sharing.", "keywords": [ "2019-nCoV", "Automation", "Biotechnology", "COVID-19", "COVID-19 detection", "COVID-19 testing", "Capital Financing", "Contact Tracing", "Cost Sharing", "Detection", "Diagnostic", "Diagnostic Equipment", "Disease Outbreaks", "Funding", "Human", "Influenza", "Investments", "Laboratories", "RADx", "RADx Tech", "RNA", "Reaction", "Reagent", "Saliva", "Specimen", "Swab", "Technology", "Testing", "Training", "United States National Institutes of Health", "detection limit", "instrument", "point of care", "point of care testing", "rapid testing", "response", "scale up", "screening" ], "approved": true } }, { "type": "Grant", "id": "8834", "attributes": { "award_id": "75N95021P00635-0-0-1", "title": "Acquisition of Smile CDR FHIR-based clinical data repository Software. FY21 procurement.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-27", "end_date": "2022-09-26", "award_amount": 174000, "principal_investigator": { "id": 24646, "first_name": "CLEMENT", "last_name": "NG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The NCATS National COVID Cohort Collaborative (N3C) Data Enclave, a centralized and secure data platform featuring powerful analytics capabilities for online discovery, visualization and collaboration for researchers studying COVID-19. The data are robust in scale and scope and are transformed into a harmonized data set to help scientists study COVID 19, including potential risk factors, protective factors and long-term health consequences. The N3C Data Enclave is anticipated to be one of the largest collections of data on COVID-19 patients in the United States. Data analysis within the enclave is supported by both R and Python, the most widely used open-source platforms for statistical analysis and data science. Researchers requesting access to, or working within, the enclave are encouraged to assemble collaborative teams with diverse expertise in such areas as clinical research, statistical analysis and informatics to make the best use of the N3C Data Enclave. A core tenet of the enclave is that it is both accessible and secure, allowing researchers to pursue research in a safe environment conducive to collaborative discovery while also allowing for the deployment of a wide variety of open source tools and components.", "keywords": [ "Area", "COVID-19", "COVID-19 patient", "Clinical Research", "Collaborations", "Data", "Data Analyses", "Data Collection", "Data Science", "Data Set", "Environment", "Fast Healthcare Interoperability Resources", "Health", "Informatics", "Pythons", "Research", "Research Personnel", "Risk Factors", "Scientist", "Secure", "Smiling", "Statistical Data Interpretation", "United States", "Visualization", "base", "clinical data repository", "cohort", "coronavirus disease", "data enclave", "data harmonization", "open source", "open source tool", "protective factors", "software repository" ], "approved": true } } ], "meta": { "pagination": { "page": 4, "pages": 1397, "count": 13961 } } }